Skip to main content
Smart Investors Daily
SI

NASDAQ · SIBN

SI-BONE, Inc.

Healthcare · Medical - Devices

$18.08

Down-$0.33 (-1.79%)

Updated Oct 3, 2026, 2:03 AM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
816.58M
P/E ratio
-33.89
Dividend yield
0.00%
52-week range
$11.48 – $21.89
Volume
547.32K
Avg. volume
529.81K

Price performance · SIBN

SIBN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 2, 2026

SIBN closed at $18.08 after 20 trading sessions, down 2.27% for the selected period.

Last close
$18.08
Period change
-2.27%
Period low
$18.04
Period high
$19.15
Daily close
View OHLC price history
SIBN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 2, 2026$18.60$18.80$17.95$18.08547.32K
Oct 1, 2026$18.87$19.04$18.27$18.41652.99K
Sep 30, 2026$19.15$19.27$18.80$18.80640.21K
Sep 29, 2026$18.92$19.60$18.61$19.15624.17K
Sep 28, 2026$18.59$18.815$18.40$18.76461.56K
Sep 25, 2026$18.44$18.76$18.285$18.59625.84K
Sep 24, 2026$18.60$18.77$18.29$18.52630.21K
Sep 23, 2026$18.76$18.81$18.145$18.60514.72K
Sep 22, 2026$18.63$18.87$18.59$18.81450.11K
Sep 21, 2026$18.19$18.55$17.82$18.45771.15K
Sep 18, 2026$17.87$18.41$17.82$18.09861.41K
Sep 17, 2026$18.81$18.86$17.95$18.04595.34K
Sep 16, 2026$18.50$18.7899$18.345$18.54411.38K
Sep 15, 2026$18.65$18.935$18.48$18.55429.41K
Sep 14, 2026$18.54$18.80$18.295$18.70550.96K
Sep 11, 2026$18.65$19.16$18.21$18.38590.91K
Sep 10, 2026$18.45$18.69$17.99$18.30686.07K
Sep 9, 2026$18.82$18.875$18.33$18.41437.52K
Sep 8, 2026$18.25$18.85$18.16$18.62541.96K
Sep 4, 2026$18.50$18.7466$18.195$18.50389.53K

Latest SIBN news

The latest Smart Investors Daily articles mentioning SIBN.

SIBN research

Overview

Company profile and research snapshot.

Company profile

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.67
Implied upside
—
Analysts
—
SIBN recent ratings
DateFirmRatingTarget
Aug 4, 2026TD CowenBuy—
Aug 4, 2026Truist SecuritiesBuy—
Aug 4, 2026UBSBuy—
Jul 28, 2026UBSBuy—
Jul 16, 2026Truist SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 28, 2026

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density boneSANTA CLARA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the iFuse Granite Onyx System (Onyx). This is SI-BONE’s first product addressing the problem of compromised bone which

Yahoo · Aug 31, 2026

SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026

SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time/ 11:30 a.m. Eastern Time. Investors interested i

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.